Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07332182 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee

Study acronym: OSTEOCONFIRM
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 2 → 10 locations
  2. Recruitment opened Show 4 more changesShow less
    • Start date: May 2026 to Sep 2026
    • Study sites: 0 to 2
    • Eligibility criteria expanded, about 39 words
    • Secondary endpoints: details revised at 8 of 10 entries
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location. The evaluation will be performed through clinical, subjective and objective assessments.
Trial Details
NCT Number NCT07332182
Lead Sponsor Fin-Ceramica Faenza Spa
Conditions
(from sponsor)		 Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis
Related terms Osteoarthritis, Osteochondritis Dissecans
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov